Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

45results about How to "Large index" patented technology

Cell Penetrating Peptide Conjugates for Delivering of Nucleic Acids into a Cell

The invention provides cell penetrating peptide-nucleic acid conjugates having the formula P-L-N, wherein P is a cell penetrating peptide, N is a nucleic acid, preferably an oligonucleotide and more preferably a siRNA, and L is a hydrophilic polymer, preferably a polyethylene glycol (PEG)-based linker linking P and N together. Compositions, methods of use and methods for producing such conjugates are also disclosed.
Owner:CELLECTIS SA

Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases

The invention is directed to compounds of formula (I) wherein X is O or NH; R' is a hydrocarbon chain; R<3 >and R<4 >are hydrogen, OH or a monosaccharide; R<5 >is hydrogen or a monosaccharide; Q' is optionally present and may be a C1-10 hydrocarbon; X' is optionally present and may be O, S or NR<8>; and Q<3 >may be a hydrocarbon or hydrogen. The invention is also directed to the use of the compounds for treating cancer, infectious diseases and autoimmune diseases. The invention is also directed to syntheses of the compounds of formula (I).
Owner:RES FOUND THE CITY UNIV OF NEW YORK +1

Method for producing high quality optical parts by casting

A casting method, rather than injection molding, to produce polymer optical components and systems is provided. The casting process controls shrinkage and stress, thus providing both high bulk uniformity and high quality, accurate surfaces, by incorporating polymer films into the mold. The films may remain incorporated into the part or may optionally be removed from the part after removal from the mold. In addition, the incorporation of separately produced components within the cast part is also provided, eliminating post-casting assembly manufacturing steps.
Owner:GOOGLE LLC

Two-dimensional surface normal slow-light photonic crystal waveguide optical phased array

Methods and devices for optical beam steering are disclosed including coupling a laser light into an apparatus comprising a first substrate; an array of air core photonic crystal waveguides; columnar members etched around each air core waveguide; a pair of metal electrodes around the columnar members; a trench around the pair of metal electrodes surrounding each air core photonic crystal waveguide; a second substrate coupled to the first substrate comprising electrical interconnection lines; and a holographic fanout array comprising a third substrate; a photopolymer film coated on the third substrate; a hologram written in the photopolymer film configured to couple the laser light into the third substrate; and an array of holograms recorded in the photopolymer film configured to couple a portion of the laser light into the waveguides; and passing a current through the electrodes to induce a refractive index change in the first substrate to control the phase of the portion of the laser light that passes through each waveguide. Other embodiments are described and claimed.
Owner:OMEGA OPTICS

Liver related disease compositions and methods

Composition and methods for use in the therapeutic and preventative treatment, study, diagnosis and prognosis of liver related disease, inflammatory disease and related conditions are disclosed. Also provided are kits and reagents for prognosis and diagnosis of liver related disease, inflammatory disease and related conditions.
Owner:PERLEGEN SCIENCES INC

Formulation of oral compositions comprising arsenic trioxide and methods of use thereof

The present invention provides an oral formulation of arsenic trioxide (As2O3) for the treatment of a variety of hematological malignancies, including acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL). The present invention also provides methods for making the oral arsenic trioxide formulation. Methods of using the oral arsenic trioxide formulation are also described.
Owner:VERSITECH LTD +1

Red-green-blue polymeric interference film

Multilayer polymeric films and other optical bodies are provided which is useful in making colored mirrors and polarizers. The films are characterized by a change in color as a function of viewing angle.
Owner:3M INNOVATIVE PROPERTIES CO

Data logging system and method thereof for heterogeneous data

The present invention provides a data logging system and a data logging method for heterogeneous data. The record file and the index file according to the present invention are constructed in such a way that the data from the log record corresponding to a given target visual data line are accessible within essentially constant time independent of the position of the visual data line within the data view, the size of the data view, the size of the log record, and the size of the record file. In the present invention, the interpreted data for each log record, occupying zero or at least one of the visual data lines, are represented within the data view continuously side by side. The computer readable medium having recorded thereon a program allowing a computer to execute the data logging method according to the present invention and the computer program product for the same are also provided.
Owner:TIBBO TECH

Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening

The invention provides methods and compositions for reducing or inhibiting bone resorption, osteoclast differentiation and stimulation and the loosening of medical prostheses by administering a compound or agent that modulates an adenosine receptor such as the adenosine A2A receptor, in particular, an agonist of an adenosine A2A receptor. The invention also extends to pharmaceutical compositions comprising such an agent that modulates an adenosine receptor such as an adenosine A2A agonist and to prosthetic devices containing such an agent that modulates an adenosine receptor such as an A2A agonist on one or more surfaces or within the prosthetic device such as, for example, suspended in the cement forming the prosthetic device.
Owner:NEW YORK UNIV

Polyethylene blends with good contact transparency

InactiveUS20050222338A1Good transparencyHigh stress crack resistanceHigh-density polyethylenePolymer blend
This invention discloses the production and use of a polyethylene composition comprising a metallocene-produced linear low density polyethylene and a multi modal high density polyethylene prepared from either a Ziegler-Natta or a metallocene catalyst system. The resulting polyethylene composition is suitable for preparing articles having improved environmental stress crack resistance, rigidity, contact transparency, gloss as well as good processing capabilities.
Owner:TOTAL RES & TECH FELUY

Derivatives of isoindigo, indigo and indirubin and methods of treating cancer

A compound called NATURA, which is a derivative of Isoindigo is useful in aiding the general health of a patient and specifically is beneficial in preventing or treating cancer. This compound and other related Isoindigo, Indigo and Indirubin derivatives are designed such that the bioactivity or bioavailability of the compound is increased. Methods of synthesizing these derivatives is also taught. In addition, pharmaceutical compositions that include a therapeutically effective amount of at least one of these derivatives and a pharmaceutically acceptable carrier. A method for the use of these pharmaceutical compositions and compounds is taught, wherein a therapeutically effective amount is administered to an animal having solid tumor cancer. The pharmaceutical composition or compound can be re-administered to the animal until a desired treatment or result is accomplished.
Owner:NATROGEN THERAPEUTICS INT

Anti-mesothelin antibodies and uses thereof

The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 4O.kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of mesothelin in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
Owner:BAYER INTELLECTUAL PROPERTY GMBH

Virus Vaccines Comprising Envelope-Bound Immunomodulatory Proteins and Methods of Use Thereof

The present invention provides novel virus vaccines with augmented, e.g., enhanced and / or extended immunogenicity. The virus vaccines of the invention comprise an envelope-bound immunomodulatory protein, e.g., a cytokine, chemokine or costimulatory molecule. The immunomodulatory protein serves as an adjuvant to augment, e.g., enhance or extend the immunogenicity of the virus vaccine, thereby augmenting, e.g., enhancing or extending immune response to the virus when administered to a subject.
Owner:WAYNE STATE UNIV

Phytoestrogenic isoflavone compositions, their preparation and use thereof for protection against and treatment of radiation injury

The present invention provides compositions and methods for the prophylactic and therapeutic treatment of animals, including humans from radiation injury. In particular, the present invention provides methods and compositions comprising the isoflavone genistein (4′,5,7-trihydroxyflavone) or phytoestrogenic isoflavonoids.
Owner:US DEPT OF HEALTH & HUMAN SERVICES +2

Optical communication system

An optical communication system for optically transmitting transmission data from a transmitting station to a transmitting device includes an adder for adding an intermediate frequency subcarrier signal modulated with data to be transmitted to a pilot carrier signal as a sinusoidal wave, and an electro-optical converter for electro-optically converting the above sum signal to an optical signal by directly modulating a semiconductor laser element having a resonant frequency fr in accordance with the sum signal and transmitting the signal to an optical fiber for a down link. The frequency fIF of the intermediate frequency subcarrier signal and the frequency fLO of the pilot carrier signal satisfyfLO−fIF≧1[GHz],2×fIF<fLO<(⅔)×fr,fIF<1[GHz], and2 [GHz]<fLO.
Owner:KK TOSHIBA

CD2 deficient african swine fever virus as live attenuated or subsequently inactivated vaccine against african swine fever in mammals

The present invention is directed to a preferably live attenuated or subsequently inactivated African swine fever virus (ASFV), comprising a non-functional genomic CD2 gene, wherein such ASFV is non deficient in its replication, as well as to corresponding compositions or immunogenic compositions or vaccines, methods of production and uses for treating and / or preventing African swine fever in mammals, preferably of the family Suidae, for instance pigs, more preferably domestic pigs (Sus scrofa domesticus), wild pigs (Sus scrofa scrofa), warthogs (Potamochoerus porcus), bushpigs (Potamochoerus larvatus), giant forest hogs (Hylochoerus meinertzhageni) as well as feral pigs.
Owner:BOEHRINGER LNGELHEIM VETMEDICA GMBH

Nucleic acid triggered catalytic drug and probe release

The present invention provides methods and combinations of compositions for the modulation of diseases caused by a subject possessing a disease-specific nucleic acid sequence. Included are methods for the treatment, prevention and / or inhibition of the diseases by administering a combination of a prodrug component, drug and catalytic component such that the drug is catalytically released when contacting the combination to the disease-specific nucleic acid sequence.
Owner:TAYLOR JOHN STEPHEN

Use of allogenic or syngenic major histocompatibility complex (MHC) molecules as universal adjuvants for vaccines against neoplastic disease, infection and autoimmune disease

The present invention is directed to the discovery that allogenic or syngenic adjuvant stimulation can cause local inflammation which increases the antigen presentation capability of cells in the vicinity of adjuvant stimulation. By discovering this phenomenon, the present invention provides a novel method for augmenting the immunogencity of an antigen by conjointly administering an allogenic or syngenic MHC molecule (as a universal adjuvant) to trigger a local inflammatory reaction to enhance antigen presentation at the site of delivery.
Owner:NEW YORK UNIV

Method for treating tumor using a combination of energy and antibody conjugated toxin

The present invention relates to a method for treating a tumor that contains fibrin. The method comprises utilizing an energy from an energy source to destroy at least a portion of (i) a fibrin contained in the tumor or (ii) fibrin surrounded tumor. The energy may also cause necrosis of tumor cells that are adjacent to the fibrin. The method further include the use of a tumor-targeting monoclonal antibody conjugated to a toxin which is administered to the subject. The present invention also relates to a method for removing and killing fibrin-associated tumor cells from a mixed cell population, which method includes the step of delivering an energy from an energy source to the fibrin-associated tumor cells and killing the tumor cells with a tumor-targeting monoclonal antibody conjugated to a toxin.
Owner:AMERICAN BIOGENETIC SCI

Methods and compositions for treating osteoarthritis and promoting cartilage formation

The invention provides methods and compositions for treating or inhibiting the development of osteoarthritis in a subject having osteoarthritis or at risk for developing osteoarthritis and for stimulating or increasing cartilage production or formation in a subject. The methods feature administering to the subject a therapeutically effective amount of a composition comprising one or more agent from among adenosine, an adenosine receptor agonist, and an agent that upregulates or increases the amount of or the biological activity of adenosine, or an analog or derivative thereof. The adenosine receptor may be an A1, A2A, A2B and A3 adenosine receptor. The agent that upregulates or increases the amount of or the biological activity of adenosine may be dipyridamole or ticagrelor. The composition may be administered via intraarticular injection such as injection into the synovial fluid of a joint. The composition may be effective to reduce or inhibit degeneration or damage to cartilage or to stimulate or increase cartilage production or formation. The composition may be a liposomal composition or contain a liposome.
Owner:NEW YORK UNIV

Illumination apparatus with gradually changeable color temperatures

The present invention provides an illumination apparatus with gradually changeable color temperatures; the apparatus includes an illumination module and a control module. The illumination module is utilized to generate an illuminating light which has a plurality of different color temperatures. The control module is utilized to control a color temperature variation of the illuminating light so that a color difference in Duv corresponding to the variation of the illuminating light is less than 0.006 under the color temperature variation. Moreover, all color rendering indices of the illuminating light corresponding to the different color temperatures are larger than 90, thereby completely simulating the variation of sun.
Owner:NAT TAIWAN UNIV OF SCI & TECH

Compositions and methods of using a soluble TNF-alpha receptor modified for increased half-life

Methods and pharmaceutical compositions for preventing and / or treating acute and chronic inflammation and autoimmune diseases are provided herein. Tumor necrosis factor-α (TNFα) promotes an inflammatory response, which causes clinical problems associated with inflammation and autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa, and refractory asthma. TNFα is also implicated in promoting pathogenesis of diabetic retinopathy leading to loss of retinal microvascular cells. Methods herein contain the step of administering a prophylactic and / or therapeutic formulation of a pharmaceutical composition containing a recombinant soluble human TNF receptor or portions thereof which are TNFα inhibitors. These pharmaceutic compositions have been modified by conjugating natural amino acids such as proline and alanine, and / or serine (PA / S) via PASylation® to create a linear polypeptide that possesses fewer of the processing, preparation, formulation, cost, and other long-term issues of administering PEGylated drugs.
Owner:DNX BIOTECH LLC

Compositions and methods for treating diseases

The present invention provides compositions and methods of use pertaining to rAAV-mediated delivery of therapeutically effective molecules for treatment of diseases such as Pompe disease. These compositions in combination with various routes and methods of administration result in targeted expression of therapeutic molecules in specific organs, tissues and cells.
Owner:UNIV OF FLORIDA RES FOUNDATION INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products